Quarterly Report · 10-Q

Autolus Therapeutics plc

Quarterly Report

Filed Aug 11, 2026Accepted Aug 11, 2026, 4:13 PM EDTCIK 1730463Accession 0001730463-26-000123

Company context

Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Current securities

AUTLNASDAQ · ADR · Current

Recent company filings

Registered securities in this filing

AUTOLUS THERAPEUTICS PLC · 10-Q · Filed 2026-08-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Ordinary shares, nominal value $0.000042 per share*

Symbol: No trading symbol declared
Exchange: NASDAQ
Classification: COMMON

Filing context

Context: c-3

Dimensions: us-gaap:StatementClassOfStockAxis

No-trading-symbol fact: true

American Depositary Shares, each representing one ordinary share, par value $0.000042 per share

Symbol: AUTL
Exchange: NASDAQ
Classification: ADS
Status: Current

Filing context

Context: c-2

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000173046326000123 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.